COMPANY

Geneoscopy

Keywords: gastroenterology Colorectal Cancer (Diagnosis) Colorectal Cancer Advanced Adenocarcinoma Serrated Polyp ColoSense

Location: St. Louis, MO · source · Oct 12, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series C · $105M · announced Jan 8, 2025 Company release ↗
Source quote
- Jan 8, 2025 · Company release ↗
  “LOUIS & HERCULES, Calif. – Jan. 8, 2025 – Geneoscopy, Inc ., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the closing of a Series C funding round raising $105 million.”

Raises announced in these releases: $105M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Sep 5, 2025 Trial start —: ColoSense Post-Approval Study source ↗
Jan 8, 2025 Raise Private equity round — Series C: $105M (total, as published), announced Jan 8, 2025. Source: company's own press page. source ↗
Jan 8, 2025 Raise Series C · $105M source ↗
Apr 12, 2021 Trial start Not phased (device or behavioral study): Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study source ↗

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $105.0M. Last 2 years.

Jan 8, 2025 Private equity round — Series C: $105M (total, as published), announced Jan 8, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07069556	ColoSense Post-Approval Study	Not listed	Recruiting	Sep 5, 2025	Sep 1, 2028 (estimated)
NCT04739722	Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study	Not phased (device or behavioral study)	Completed	Apr 12, 2021	Oct 27, 2022 (actual)